Matsuo Koji, Takazawa Yutaka, Ross Malcolm S, Elishaev Esther, Yunokawa Mayu, Sheridan Todd B, Bush Stephen H, Klobocista Merieme M, Blake Erin A, Takano Tadao, Baba Tsukasa, Satoh Shinya, Shida Masako, Ikeda Yuji, Adachi Sosuke, Yokoyama Takuhei, Takekuma Munetaka, Yanai Shiori, Takeuchi Satoshi, Nishimura Masato, Iwasaki Keita, Johnson Marian S, Yoshida Masayuki, Hakam Ardeshir, Machida Hiroko, Mhawech-Fauceglia Paulette, Ueda Yutaka, Yoshino Kiyoshi, Kajiwara Hiroshi, Hasegawa Kosei, Yasuda Masanori, Miyake Takahito M, Moriya Takuya, Yuba Yoshiaki, Morgan Terry, Fukagawa Tomoyuki, Pejovic Tanja, Nagano Tadayoshi, Sasaki Takeshi, Richmond Abby M, Post Miriam D, Shahzad Mian M K, Im Dwight D, Yoshida Hiroshi, Omatsu Kohei, Ueland Frederick R, Kelley Joseph L, Karabakhtsian Rouzan G, Roman Lynda D
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, USA.
Department of Pathology, Cancer Institute Hospital, Tokyo, Japan.
Surg Oncol. 2018 Sep;27(3):433-440. doi: 10.1016/j.suronc.2018.05.017. Epub 2018 May 11.
To examine significance of sarcoma dominance (SD) patterns in uterine carcinosarcoma (UCS).
This is a secondary analysis of multicenter retrospective study examining women with stages I-IV UCS who underwent primary surgery. SD was defined as >50% of sarcoma component in uterine tumor. SD patterns were grouped as homologous sarcoma without SD (homo/non-dominance, n = 351), heterologous sarcoma without SD (hetero/non-dominance, n = 174), homologous sarcoma with SD (homo/dominance, n = 175), and heterologous sarcoma with SD (hetero/dominance, n = 189), and correlated to tumor characteristics and survival.
SD patterns were significantly associated with age, body habitus, carcinoma type, tumor size, depth of myometrial invasion, and nodal metastasis (all, P < 0.05). On univariate analysis, SD was associated with decreased progression-free survival (PFS) and cause-specific survival (CSS) in homologous cases (both, P < 0.05) but not in heterologous cases. On multivariate models, both homologous and heterologous SD patterns remained independent prognostic factors for decreased PFS (adjusted-hazard ratio [HR] ranges: homo/dominance 1.35-1.69, and hetero/dominance 1.47-1.64) and CSS (adjusted-HR ranges: 1.52-1.84 and 1.66-1.81, respectively) compared to homo/non-dominance (all, P < 0.05). Among stage I-III disease, when tumors had SD, adding radiotherapy to chemotherapy was significantly associated with improved PFS (adjusted-HR: homo/dominance 0.49, and hetero/dominance 0.45) and CSS (0.36 and 0.31, respectively) compared to chemotherapy alone (all, P < 0.05); contrary, this association was not observed with absence of SD (all, P > 0.05).
In UCS, SD impacts survival in homologous but not in heterologous type. Regardless of sarcoma types, SD was associated with decreased survival in UCS; adding radiotherapy to chemotherapy may be an effective postoperative strategy.
探讨肉瘤优势(SD)模式在子宫癌肉瘤(UCS)中的意义。
这是一项多中心回顾性研究的二次分析,研究对象为接受初次手术的I-IV期UCS女性患者。SD定义为子宫肿瘤中肉瘤成分>50%。SD模式分为无SD的同源肉瘤(同源/非优势型,n = 351)、无SD的异源肉瘤(异源/非优势型,n = 174)、有SD的同源肉瘤(同源/优势型,n = 175)和有SD的异源肉瘤(异源/优势型,n = 189),并与肿瘤特征和生存率相关联。
SD模式与年龄、体型、癌类型、肿瘤大小、肌层浸润深度和淋巴结转移显著相关(均P < 0.05)。单因素分析显示,同源病例中SD与无进展生存期(PFS)和病因特异性生存期(CSS)降低相关(均P < 0.05),而异源病例中无此关联。多因素模型显示,与同源/非优势型相比,同源和异源SD模式均为PFS降低(校正风险比[HR]范围:同源/优势型1.35 - 1.69,异源/优势型1.47 - 1.64)和CSS降低(校正HR范围:分别为1.52 - 1.84和1.66 - 1.81)的独立预后因素(均P < 0.05)。在I-III期疾病中,当肿瘤有SD时,与单纯化疗相比,化疗联合放疗与PFS改善(校正HR:同源/优势型0.49,异源/优势型0.45)和CSS改善(分别为0.36和0.31)显著相关(均P < 0.05);相反,无SD时未观察到这种关联(均P > 0.05)。
在UCS中,SD影响同源型而非异源型的生存。无论肉瘤类型如何,SD均与UCS生存率降低相关;化疗联合放疗可能是一种有效的术后策略。